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ABSTRACT
Objective: Adverse drug reactions (ADRs) can lead to many complications associated with the use of medications. In Iraq, where a wide range of 
medications misused widely due to different reasons, the Iraqi Pharmacovigilance (PV) program started out few years ago to collect information about 
adverse drugs reactions and since the success of this program depends on the effective participation of all medical staffs including pharmacists in this 
program. This study aimed to assess the knowledge, attitude, and degree of awareness of Iraqi pharmacists in Baghdad community toward adverse 
drugs reactions monitoring and PV program.
Methods: This study was a cross-sectional descriptive survey based on individual questionnaire that administered in English to a convenience sample 
of 150 pharmacists working in 3 colleges of pharmacy, 20 community pharmacies, and 3 hospitals situated in different areas of Baghdad which is the 
capital of Iraq. The questionnaire consists of three parts that collect demographic data on the participants and their knowledge, attitudes toward PV.
Results: Although about 62% of pharmacists have observed ADRs in their practice, only half of the respondents have heard about the term PV, 
48% were aware of the national PV program. Moreover, 47.33% of the respondents mentioned that ADRs associated with herbal products should 
not be reported. Although 79% of the respondents thought that reporting ADRs are a pharmacist’s duty nevertheless 82% of them thought that 
ADRs reporting in Iraq are not widely promoted by the relevant authority. The study showed high tendency for participation in and ADR monitoring 
program. Interestingly, 60% of respondents report that their workplace does not encourage them for reporting ADRs while 48% of respondents 
indicated that they do not have enough time for reporting ADRs and 38% of them declared their fearing of facing legal problem from that.
Conclusion: Iraqi pharmacists although have a high tendency in participation in ADRs monitoring program but have a poor knowledge about PV 
practices; they lack understanding of the details about the national PV  system and ADRs reporting process and may need more information on how 
ADRs reporting are performed.
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INTRODUCTION
Medicines have substantial benefits to human health; however, most 
times, adverse reactions or unwanted effects produced with their 
beneficial effect [1].
This adverse drug reaction (ADR) or unwanted effect simply can be 
defined as an injury caused by taking a medication [2]. This usually 
can lead to many complications associated with the use of medicines 
such as the increase in the duration of hospital stay [3] and hospital 
costs [4]. Moreover, ADRs can lead to death in about 2.9% of hospital 
admissions [5]. Although ADRs are preventable, still regarded as one 
the top 10 leading causes of mortality in many countries [6].
After the “thalidomide tragedy,” many countries have established 
drug monitoring systems (Pharmacovigilance [PV] system) for 
early detection and prevention of possible drug-related morbidity 
and mortality and to minimize the financial costs associated with 
preventable adverse events [7]. During the last decade, PV activities 
have evolved widely and the postmarketing surveillance (PV system) 
help many drug companies to frame the full benefit-risk profile of their 
drugs in the real world setting which is more effective than clinical 
trials that only help a company in initial reporting of safety profile [8].
The WHO establish education center in the Netherlands, to develop PV 
curricula for medical school to overcome the inefficiency of training and 
education of medical staffs regarding ADRs monitoring [9]. There are 
differences among countries in the occurrence of ADRs and other drug-
related problems [10]. In Iraq, which is one of the third world countries, 
the dispensing of many medications is illegal, and many people stored 
medications in their houses in inappropriate storage conditions; 
furthermore, they use it most times incorrectly without any physician 
advice [11]. In one study that evaluate the use of analgesics by Iraqi 
people, the result showed a misuse of using these medications and most 
consumers have no information about the side effect, even more higher 
percentage of them do not adhere to doses prescribed [12].
The former two studies showed that the Iraqi people have a high 
affinity to confront ADRs as a result of their misuse of medications; 
so to decrease the impact of this dilemma, the Iraqi PV center has 
been established in the Directorate of technical affairs, Ministry of 
Health (MOH) to be responsible for the collection, and evaluation 
of information on pharmaceutical products marketed in Iraq, with 
particular reference to adverse reactions [13].
As the success of any PV system depends on the cooperation of all 
medical professions including pharmacists in reporting suspecting 
ADRs, especially to new drugs [14].
Many studies conclude that improving hospital and community 
pharmacist knowledge and experiences toward ADRs reporting can 
play a significant role in the prevention of ADRs in addition to improving 
other healthcare professionals’ knowledge about ADRs reporting [15].
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This study is the foremost study  in Iraq designed to evaluate the 
knowledge of Iraqi pharmacists in Baghdad community toward ADRs 
monitoring program (PV system) and assess their attitude to participate 
in this program.
METHODS
This study was a cross-sectional descriptive survey based on individual 
questionnaire developed by authors of this study based on multiple 
pretested questionnaires in similar literatures. The questionnaire 
approved by Scientific Committee in Department of Clinical Pharmacy, 
college of Pharmacy, Baghdad University (Tables 1-3).
The questionnaire administered in English to a convenience sample 
of 150 pharmacists working in 3 colleges of pharmacy, 20 community 
pharmacies, and 3 hospitals situated in different areas of Baghdad 
which is the capital of Iraq. The study sample was collected during 
the periods from November 2015 to September 2016. The study was 
approved by the Ethics and Research Committee in the Department 
of Clinical Pharmacy, College of Pharmacy, Baghdad University. Verbal 
consent was obtained from all participants who agreed to participate 
in the study after explaining the objectives, importance, and benefits 
of this study. Participants were told that all information provided was 
completely confidential with a nameless presentation of the results. 
The questionnaire consists of three parts that collect demographic data 
on the participants and their knowledge, attitudes toward PV.
Statistical analysis
The collected data from the completed questionnaires were assessed 
for descriptive statistics such as frequencies and percentages. Statistical 
analysis was analyzed using Microsoft Excel program 2013.
RESULTS
Participants’ demographic data
The questionnaire administered to 200 pharmacists, but only 
150 accept to fill it. The response rate of the survey was 75%. The age 
of pharmacists participated ranging from 23 to 65 years. The highest 
percentage was females (56.7%), qualified as bachelor pharmacists 
(63.3%) and with work experience more than 10 years (43.3%). Details 
of the respondents’ demographic profile are illustrated in Table 1.
Knowledge of ADR reporting and monitoring by respondents
Half of the respondents have heard about PV, 43.33% were aware of the 
national PV program. On the other hand, 34.67% of the respondents 
mentioned that ADRs associated with herbal products should not be 
reported, whereas 74% thought that the responsible organization for 
monitoring ADRs is MOH as shown in Table 2.
Attitudes toward ADR reporting
Table 3 shows that 79% of the respondents thought that reporting ADRs 
is a pharmacist’s duty and 82% who thought that ADRs reporting in Iraq 
is not widely promoted by relevant authority whereas 74% declared 
their interest in the participation in ADR reporting system, 62% have 
Table 1: Demographic characteristics of the respondents
Characteristics Category Total N (%)
Gender Male 65 (43.3)
Female 85 (56.7)
Age 23-33 63 (42)
34-44 48 (32)
>44 39 (26)




Work experience 1-5 years 51 (34)
6-10 years 34 (22.6)
>10 years 65 (43.3)





Table 2: Knowledge of ADRs reporting and monitoring by respondents
Identified knowledge Responses, N (%)
Yes No Not sure
Did you hear about the term PV? 76 (50.67) 61 (40.67) 13 (8.66)
Are you aware about the national PV program? 65 (43.33) 66 (44) 19 (12.67)
Do you think that ADRs associated with herbal 
products should not be reported in PV?




Who do you think the responsible organization 
for collecting and monitoring ADRs in Iraq?
24 (16) 111 (74) 15 (10)
Sample size N=150. PV: Pharmacovigilance, ADR: Adverse drug reactions, MOH: Ministry of Health
Table 3: Responses of respondents to the attitude related questions 
Identified attitudes Responses, N (%)
Yes No Not sure
Do you think that reporting ADR is a pharmacist duty? 119 (79.33) 15 (10) 16 (11.67)
Do you think that ADR reporting in Iraq is not widely 
promoted by relevant authorities?
124 (82.67) 14 (9.33) 12 (8)
Are you interested in participating in the ADR reporting 
system?
111 (74) 26 (17.33) 13 (8.67)
Have you observed ADRs cases in your practice? 94 (62.67) 39 (26) 17 (11.33)
Does your work place encourage you to report an ADR? 38 (25.33) 91 (60.67) 21 (14)
Do you think that pharmacists do not have enough time? 72 (48) 67 (44.67) 11 (7.33)
Are you afraid of facing legal problems from that? 57 (38) 65 (43.33) 28 (18.67)
Sample size N=150. ADR: Adverse drug reactions
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observed ADRs in their practice; however, 60% of respondents report 
that their workplace does not encourage them for reporting ADRs, 48% 
of respondents showed that they do not have enough time for reporting 
ADRs, and 38% of them declared their fearing of facing legal problem 
from that.
DISCUSSION 
This cross-sectional survey was conducted with a convenience sample 
of 150 pharmacists to collect information on what they know, believe, 
and do regarding adverse drugs reaction monitoring and the Iraqi PV 
program. The present study is similar to previous studies conducted 
in Yemen [16], many developing countries [17,18], and developed 
countries [19,20].
The study has shown a gap in the knowledge of Iraqi pharmacists 
about ADRs monitoring center in Iraq and PV system and about 44% 
of participants do not have a full knowledge about this center and 47% 
of them did not think that they are responsible for reporting adverse 
reactions related to herbal products. Although these percentages 
regarded low in comparison to another studies performed other 
countries like in Saudi Arabia where 78.8% did not know that 
pharmacists can submit ADRs reports online [21] or in a pilot study 
conducted in Turkey, where only 17.2% of the pharmacists had any 
knowledge about “PV” [18] in addition to a similar study conducted in 
Yemen, where 69% of pharmacists unaware of national PV program [16].
Inadequate knowledge of healthcare professionals is most probably 
due to the fact that drug safety is not taken seriously worldwide, 
particularly in developing countries [17,18] although it should be one 
of the top priorities in healthcare programs.
Furthermore, the PV center activities are still inadequate with 
no sufficient advertising about it in Iraq. Despite the findings of 
relatively high rates of unawareness and inadequate knowledge 
among participants, 79% of them thought that reporting ADRs is a 
pharmacist’s duty and that similar to many previous studies have 
shown that while the right attitude for ADR reporting exists among 
most of the pharmacists and physicians, the actual practice of ADRs 
reporting is lacking [17]. The main problem faced national PV  systems 
worldwide is underreporting [2].
Although high percentage (79%) of participant said that reporting 
adverse drug reaction is a pharmacist duty and more than 62.67% 
observe ADR during their normal work, all of them did not report these 
ADR and that similar to many studies in India [17], Mumbai [22], and 
Ahmedabad [23] have shown that prescribers have high knowledge and 
attitude with regard to ADRs reporting but practice it poorly. This can 
be attributed to many reasons such as unawareness of the existence 
of a national ADRs reporting system, the workplace did not encourage 
them to report an ADR as 60.67, also about 38% of participants afraid 
of facing legal problems from that  or they do not have enough time to 
report these ADRs (48%). 
The effectiveness of PV activities in a country is directly dependent 
on the active participation of healthcare professionals, patients, and 
consumers [24]. Fortunately, all respondents in this study were in favor 
of the idea of setting up the ADRs reporting system in Iraq and about 
three quarters of them were willing to be involved in the implementation 
of the system in Iraq. To improve Iraqi patient’s safety and quality of life, 
pharmacists and other medical staffs need educational programs and 
training to improve their knowledge about ADRs monitoring process 
to encourage them to be involved in this task. These were similar to 
the results of a study conducted in Nigeria [25], which showed the role 
of continuous medical education; training programs for medical staffs 
to report ADRs and helped in improving patient’s safety and medical 
care.  Furthermore, the center must take his role to raise the awareness 
of Iraqi patients to improve patient self- reporting manner to increase 
the reporting of ADRs. The benefits of this idea have been confirmed in 
different studies [26,27].
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